新型冠状病毒肺炎经鼻高流量氧疗:机遇和挑战

High-flow nasal cannula oxygen therapy in coronavirus disease 2019:opportunities and challenges

新型冠状病毒肺炎(COVID-19)是自2019年末以来我国新出现的乙类传染病,随着对该疾病临床特点及病理学等的进一步认识,发现在临床救治中应给予患者及时和恰当的氧疗.经鼻高流量氧疗在既往新发呼吸道传染病引发的呼吸衰竭,特别是病毒性肺炎救治中取得良好效果,在本次新型冠状病毒疫情中也有使用并取得一定临床疗效,该治疗也存在应用时机和风险评估等诸多挑战.经鼻高流量氧疗作为一项临床广泛应用的氧疗措施,其应用前景广阔,但仍需进一步研究其恰当的适应证与风险评估.

The coronavirus disease 2019(COVID-19)is a novel infectious diseases that has been lassified into b class of transmitted disease since its outbreak in our country at the end of 2019.Along with the ongoing deeper cognition of clinical characteristics and pathology of the disease,we gradually realize that the patients should be given timely and appropriate oxygen therapy.High flow nasal cannula oxygen therapy(HFNC)has brought good therapeutie efet in the patient with acute respiratory failure caused by the newly emerging respiratory infections disease,especially the viral pneumonia.Impressively,it was used for the patient with the COVID-19 during the outbreak,bringing a satisfactory clinical curative outcome.However,with the more comprchensively cognition of the disease and the therapy,many challenges,such as the timing of application and the risk assessment,have emerged.HFNC,as a widely-utilized clinical oxygen therapy,has wide prospect of application,but still need further researches that focus on the appropriate clinical indications and the risk assessment.